GSK denies claims it is turning to the developing world for TIDE study patients
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has refuted charges that the TIDE comparative clinical trial for its diabetes drug Avandia (rosiglitazone) is adding sites in developing nations such as India following a shortfall in patient enrolment in the US and other developed markets amid ethical and safety concerns over the study.